Sumary of Investigational Ebola Vaccine Regimen Shows Immune Response in Kids and Adults:
- Johnson (J&J) reported its Ebola vaccine regimen, Ad26.ZEBOV (Zabdeno) and MVA-BN-Filo (Mvabea), generated humoral immune responses in adults and children, ages 1-17, with the immune responses persisting in adults for at least two years.
- This data comes from the phase 3 EBOVAC-Salone clinical study which was conducted in Sierra Leone and the results were published in The Lancet Infectious Diseases.
- Johnson Vice Chairman of the Executive Committee and Chief Scientific Officer Paul Stoffels, MD, said in a statement.
- Phase 3 Study ParametersThis study was conducted to determine the safety and immunogenicity of the two-dose, heterologous vaccine regimen.
- Consenting adults participating in stage one of the study were administered a booster dose of A26.ZEBOV two years after the first dose.
- “Vaccine-induced humoral immune responses were observed in 41 (98%) of 42 stage 1 participants (geometric mean binding antibody concentration 4784 ELISA units [EU]/mL [95% CI 3736–6125]) and in 176 (98%) of 179 stage 2 participants (3810 EU/mL [3312–4383]) at 21 days after the second vaccination,” the investigators wrote in the study.
- “Recent and ongoing outbreaks in Africa underscore that the threat of Ebola is not going away, which is why we collaborated to develop a vaccine regimen capable of inducing long-term immunity against Ebola and are now working to ensure that it is accessible to people in need,” Stoffels stated.